Table 1: Demographic Characteristics and Clinical Characteristics of the Patients (N (%))
|
|
Fatigue Group |
p |
||
|
None/Mild (N=28) |
Moderate (N=41) |
Severe (N=16) |
||
|
Demographic Characteristics |
||||
|
Age (years)* |
46.9 (12.1) |
48.3 (9.6) |
49.8 (13.3) |
0.718 |
|
Female |
14 (50) |
21 (51) |
8 (50) |
0.994 |
|
Education (years)* |
13.8 (3.2) |
13.3 (3.4) |
12.9 (2.4) |
0.623 |
|
FSIQ |
105.3 (13.4) |
103.6 (12.9) (N=39) |
101.4 (13.5) (N=15) |
0.647 |
|
Married |
20 (71) |
23 (56) |
12 (75) |
0.269 |
|
Clinical Characteristics |
||||
|
WHO Grade 1 |
1 (4) |
3 (7) |
5 (31) |
0.151 |
|
WHO Grade 2 |
11 (39) |
24 (59) |
3 (19) |
|
|
WHO Grade 3 |
8 (29) |
8 (20) |
4 (25) |
|
|
WHO Grade 4 |
8 (29) |
6 (15) |
4 (25) |
|
|
Tumor Side – Left |
10 (36) |
15 (37) |
4 (25) |
0.840 |
|
Tumor Side – Right |
13 (46) |
18 (44) |
10 (63) |
|
|
Tumor Side - Both |
5 (18) |
8 (20) |
2 (13) |
|
|
Radiotherapy |
23 (82) |
29 (71) |
14 (88) |
0.309 |
|
Chemotherapy |
8 (29) |
13 (32) |
8 (50) |
0.319 |
|
Years since diagnosis** |
5 (2.0-10.5) |
6 (2.0-14.0) |
8 (5.5-16.5) |
0.410 |
|
Years since treatment** |
4.1 (1.5-6.0) |
4.5 (2.0-11.9) |
5.7 (2.0-11.0) |
0.653 |
|
Anti-epileptic drug use |
||||
|
Current use |
16 (57) |
28 (68) |
9 (56) |
0.551 |
|
Other medications |
||||
|
Steroid |
1 (4) |
5 (12) |
3 (9) |
0.265 |
|
Anti-depressant |
2 (7) |
3 (7) |
5 (31) |
0.052 |
|
Statin |
3 (11) |
5 (12) |
2 (13) |
0.999 |
|
Diabetes |
1 (4) |
5 (12) |
2 (13) |
0.540 |
|
Anti-anxiety |
2 (7) |
3 (7) |
1 (6) |
0.999 |
|
Blood pressure |
2 (7) |
4 (10) |
2 (13) |
0.890 |
Abbreviations: FSIQ Full Scale IQ estimated from the Test of Premorbid Functioning
*mean (SD), **median (interquartile range)